成人呼吸道合胞病毒感染:叙述性综述
该叙述性综述指出,RSV是影响各年龄段的RNA病毒,经飞沫传播,在成人尤其是合并症的老年人中日益被认识为重要病原体。仅凭临床无法足够准确区分RSV与其他急性病毒感染,参考标准诊断为PCR,床旁检测在病毒载量低时性能较差,单一呼吸道部位采样可能低估。RSV占老年人(≥60岁或≥65岁,依研究而定)门诊呼吸道感染就诊的6-11%,占成人(≥18岁)呼吸道感染住院的4-11%,其中6-15%入住ICU,占所有RSV呼吸道感染住院成人的1-12%死亡。目前缺乏循证RSV特异性治疗,以支持治疗为主;2023年两种蛋白亚单位疫苗获批用于≥60岁成人预防重症RSV,第三种mRNA疫苗近期在美国获批上市,3期研究显示对重症疾病有良好保护。
要点
- 仅凭临床无法足够准确区分RSV与其他急性病毒感染,参考标准诊断为PCR,床旁检测在病毒载量低时性能较差。
- RSV占老年人(≥60岁或≥65岁,依研究而定)门诊呼吸道感染就诊的6-11%,占成人(≥18岁)呼吸道感染住院的4-11%。
- 住院成人RSV呼吸道感染中6-15%入住ICU,占所有RSV呼吸道感染住院成人的1-12%死亡。
- 与流感住院者相比,重症RSV住院者通常更年长(多数≥60岁)、合并症更多、呼吸道症状更多且常无发热。
- 目前缺乏循证RSV特异性治疗,以支持治疗为主;2023年两种蛋白亚单位疫苗获批用于≥60岁成人预防重症RSV。
适用人群与场景
- 成人,尤其是合并症的老年人;门诊数据涉及老年人(≥60岁或≥65岁,依研究而定),住院数据涉及成人(≥18岁)。
- 社区研究估计高收入国家≥60岁成人RSV感染年发病率约3-7%。
诊断标准与关键阈值
- 参考标准诊断为PCR;床旁检测在病毒载量低时性能较差;单一呼吸道部位采样可能导致漏检。
处置流程与药物剂量
- 目前缺乏循证RSV特异性治疗,以支持治疗为主要方式。
- 2023年两种蛋白亚单位疫苗获批用于≥60岁成人预防重症RSV;第三种mRNA疫苗近期在美国获批上市,3期研究显示对重症疾病有良好保护。
红旗征与不能漏的情况
- 住院成人RSV呼吸道感染中6-15%入住ICU,占所有RSV呼吸道感染住院成人的1-12%死亡。
- 长期后遗症常见,包括基础疾病恶化(典型为心力衰竭和COPD)。
研究设计与关键结果
- 叙述性综述:RSV占老年人(≥60岁或≥65岁,依研究而定)门诊呼吸道感染就诊的6-11%,占成人(≥18岁)呼吸道感染住院的4-11%,其中6-15%入住ICU,占所有RSV呼吸道感染住院成人的1-12%死亡。
- 社区研究估计高收入国家≥60岁成人RSV感染年发病率约3-7%。
- 与流感相比成人疾病负担相似,但重症RSV住院者通常更年长(多数≥60岁)、合并症更多、呼吸道症状更多且常无发热。
- 三种疫苗(两种蛋白亚单位疫苗和一种mRNA疫苗)的3期研究显示对重症疾病有良好保护。
证据类型、等级与局限
- 证据类型:叙述性综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,需要真实世界疫苗有效性数据(包括RSV相关住院高风险亚组)以确定新获批RSV疫苗的最佳使用。
- 作者认为,亟需将RSV从「对儿童严重但对老年人远不如流感重要」的观念转变为「RSV也是老年人健康的重大风险,需要针对性预防和治疗」。
- 作者认为,新诊断和治疗手段需在目标人群中严格评估,以确保仅用于有证据显示改善结局者。
指南或共识出处
- Lancet Respir Med 发表的叙述性综述(标题:成人呼吸道合胞病毒感染:叙述性综述)。
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Respiratory syncytial virus (RSV), an RNA virus spread by droplet infection that affects all ages, is increasingly recognised as an important pathogen in adults, especially among older people living with comorbidities. Distinguishing RSV from other acute viral infections on clinical grounds alone, with sufficient precision to be clinically useful, is not possible. The reference standard diagnosis is by PCR: point-of-care tests perform less well with lower viral loads. Testing samples from a single respiratory tract site could result in underdetection. RSV is identified in 6-11% of outpatient respiratory tract infection (RTI) consultations in older adults (≥60 years, or ≥65 years, depending on the study) and accounts for 4-11% of adults (≥18 years) hospitalised with RTI, with 6-15% of those hospitalised admitted to intensive care, and 1-12% of all adults hospitalised with RSV respiratory tract infection dying. Community-based studies estimate the yearly incidence of RSV infection at around 3-7% in adults aged 60 years and older in high-income countries. Although RSV accounts for a similar disease burden as influenza in adults, those hospitalised with severe RSV disease are typically older (most ≥60 years) and have more comorbidities, more respiratory symptoms, and are frequently without fever. Long-term sequelae are common and include deterioration of underlying disease (typically heart failure and COPD). There are few evidence-based RSV-specific treatments currently available, with supportive care being the main modality. Two protein subunit vaccines for protection from severe RSV in adults aged 60 years and older were licensed in 2023, and a third-an mRNA-based vaccine-recently gained market approval in the USA. The phase 3 studies in these three vaccines showed good protection against severe disease. Data on real-world vaccine effectiveness in older adults, including subgroups at high risk for RSV-associated hospitalisation, are needed to establish the best use of these newly approved RSV vaccines. New diagnostics and therapeutics are being developed, which will also need rigorous evaluation within their target populations to ensure they are used only for those in whom there is evidence of improved outcomes. There is an urgent need to reconceptualise this illness from one that is serious in children, but far less important than influenza in older people, to thinking of RSV as also a major risk to health for older people that needs targeted prevention and treatment.
参考来源
- Wildenbeest JG, Lowe DM, Standing JF, et al. Respiratory syncytial virus infections in adults: a narrative review. Lancet Respir Med. 2024. PMID: 39265602. doi:10.1016/S2213-2600(24)00255-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。